Advertisement
Advertisement
GSK
GSK plc - ADR
50.54
USDSponsored
-0.70
-1.37%
May 29, 16:00 UTC -4
Closed
After-Market
51.03
+0.49
+0.97%
GSK Earnings Reports
Positive Surprise Ratio
GSK beat 34 of 41 last estimates.
83%
Next Report
Date of Next Report
Jul 29, 2026
Estimate for Q2 26 (Revenue/ EPS)
$8.52B
/$0.47
Implied change from Q1 26 (Revenue/ EPS)
+11.70%
/+2.17%
Implied change from Q2 25 (Revenue/ EPS)
+6.71%
/+2.17%
GSK plc - ADR earnings per share and revenue
On Apr 29, 2026, GSK reported earnings of 0.46 USD per share (EPS) for Q1 26, beating the estimate of 0.44 USD, resulting in a 3.84% surprise. Revenue reached 7.63 billion, compared to an expected 7.82 billion, with a -2.43% difference. The market reacted with a -5.64% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 5 analysts forecast an EPS of 0.47 USD, with revenue projected to reach 8.52 billion USD, implying an increase of 2.17% EPS, and increase of 11.70% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Roivant Sciences Ltd. Common Shares
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.35
Actual
-$0.57
Surprise
-64.63%
Belite Bio, Inc - ADR
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.64
Actual
-$0.68
Surprise
-4.87%
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
May 22, 2026 For Q1 26
Estimate
-$1.53
Actual
-$2.35
Surprise
-53.05%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
OS Therapies Incorporated
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.27
Surprise
-49.83%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
EVOGENE LTD.
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.60
Surprise
-117.86%
FAQ
What were GSK plc - ADR's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, GSK plc - ADR reported EPS of $0.46, beating estimates by 3.84%, and revenue of $7.63B, -2.43% below expectations.
How did the market react to GSK plc - ADR's Q1 2026 earnings?
The stock price moved down -5.64%, changed from $54.47 before the earnings release to $51.40 the day after.
When is GSK plc - ADR expected to report next?
The next earning report is scheduled for Jul 29, 2026.
What are the forecasts for GSK plc - ADR's next earnings report?
Based on 5
analysts, GSK plc - ADR is expected to report EPS of $0.47 and revenue of $8.52B for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement